Cardiovascular morbidity and the use of inhaled bronchodilators

International Journal of COPD

Volumn 3, Issue 1, 2008, Pages 163-169

  Macie, Christine ^a   Wooldrage, Kate ^a   Manfreda, Jure ^a   Anthonisen, Nicholas ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Bronchodilator therapy; Inhaled corticosteroids; Nested case control study

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HYPOCHOLESTEROLEMIC AGENT; IPRATROPIUM BROMIDE; NITRATE;

ADULT; ARTICLE; ASTHMA; BRONCHITIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLLAGEN DISEASE; COMORBIDITY; CONTROLLED STUDY; DEMENTIA; DIABETES MELLITUS; FEMALE; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PEPTIC ULCER; SUPRAVENTRICULAR TACHYCARDIA;

ADMINISTRATION, INHALATION; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DATABASES, FACTUAL; FEMALE; HOSPITALIZATION; HUMANS; MALE; MANITOBA; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 42149094428     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Anthonisen NR, Connett JE, Enright PL, et al. 2002. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med, 166:333-9.
2. Au DH, Curtis JR, Every NR, et al. 2002. Association between inhaled β-agonists and the risk of unstable angina and myocardial infarction. Chest, 121:846-51.
3. Au DH, Udris EM, Fan VS, et al. 2003. Risk of mortality and patients with known left ventricular systolic dysfunction. Chest, 123:1964-9.
4. Au DH, Udris EM, Curtis JR, et al. 2004. Association between chronic heart failure and inhaled β-2 adrenoceptor agonists. Am Heart J, 148:915-20.
5. Coleman AJ, Leary UP, Kaul DS. 1975. Hemodynamic effects of Sch 1000 in normal subjects. Postgrad Med J, 51(Suppl 7): 121.
6. Coughlin SS, Metayer C, McCarthy EP, et al. 1995. Respiratory illness, β-agonists and risk of idiopathic dilated cardiomyopathy. Am J Epidemiol, 142:395-403.
7. Curkendall SM, DeLuise C, Jones JK, et al. 2006. Cardiovascular disease in patients with chronic obstructive lung disease, Saskatchewan Canada. Ann Epidemiol, 16:63-70.
8. Guite HF, Dundas R, Burney PGJ. 1999. Risk factors for death from asthma, chronic obstructive pulmonary disease, and cardiovascular disease after a hospital admission for asthma. Thorax, 54:301-7.
9. Hudson LD, Kurt TL, Petty TL, et al. 1973. Arrhythmias associated with acute respiratory failure in patients with chronic airway obstruction. Chest, 63:661-5.
10. Huzel L, Roos LL, Anthonisen NR, et al. 2002. Diagnosing asthma: the fit between survey and administrative database. Canad Respir J, 9:407-12.
11. Iskandar SB, Mathai MG, Byrd RP, et al. 2004. Myocardial injury during standard treatment of an adult with status asthmaticus. J Asthma, 41:337-42.
12. Kallergis EM, Manios EG, Kanoupakis EM, et al. 2005. Acute electrophysiologic effects of inhaled salbutamol in humans. Chest, 127:2057-63.
13. Kleiger RE, Senior RM. 1974. Long term electrocardiographic monitoring of ambulatory patients with chronic airway obstruction. Chest, 65:483-7.
14. Macie C, Wooldrage K, Manfreda J, et al. 2006. Inhaled corticosteroids and mortality in COPD. Chest, 130:640-6.
15. Ringbaek T, Viskum K. 2003. Is there any association between inhaled ipratropium and mortality in patients with COPD and asthma? Resp Med, 97:264-72.
16. Robin ED, McCauley R. 1992. Sudden cardiac death in bronchial asthma, and inhaled beta-adrenergic agonists. Chest, 101:1699-702.
17. Salpeter SR, Ormiston TM, Salpeter EE. 2004. Cardiovascular effects of β-agonists in patients with asthma and COPD. A meta-analysis. Chest, 125:2309-21.
18. Sin DD, Tu JV. 2000. Lack of association between ipratropium bromide and mortality in elderly patients with chronic obstructive airway disease. Thorax, 55:194-7.
19. Sin DD, Mann SFP. 2003. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? Circulation, 107:1514-9.
20. Sin DD, Wu L, Mann SFP. 2005. The relationship between reduced lung function and cardiovascular mortality. A population-based study and a systematic review of the literature. Chest, 127:1952-9.
21. Suissa S, Ernst P, Boivin JF, et al. 1994. A cohort analysis of excess mortality in asthma and the use of inhaled β-agonists. Am J Respir Crit Care Med, 149:604-10.
22. Suissa S, Hemmelgarn B, Blais L, et al. 1996. Bronchodilators and acute cardiac death. Am J Respir Crit Care Med, 154:1598-602.
23. Suissa S, Assimes T, Ernst P. 2003. Inhaled short acting β-agonist use in COPD and the risk of acute myocardial infarction. Thorax, 58:43-6.
24. [WHO] World Health Organisation. 1978. International classification of diseases, 9th revision. Geneva: WHO.
25. [WHO] World Health Organization. 1995. World Health Organization's Centre for Drug Statistics Methodology: Guidelines for ATC classification and DDD assignment. Oslo, Norway: WHO.